These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Improvement in β-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Rickels MR; Liu C; Shlansky-Goldberg RD; Soleimanpour SA; Vivek K; Kamoun M; Min Z; Markmann E; Palangian M; Dalton-Bakes C; Fuller C; Chiou AJ; Barker CF; Luning Prak ET; Naji A Diabetes; 2013 Aug; 62(8):2890-7. PubMed ID: 23630300 [TBL] [Abstract][Full Text] [Related]
12. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786 [TBL] [Abstract][Full Text] [Related]
13. Improving efficacy of clinical islet transplantation with iodixanol-based islet purification, thymoglobulin induction, and blockage of IL-1β and TNF-α. Matsumoto S; Takita M; Chaussabel D; Noguchi H; Shimoda M; Sugimoto K; Itoh T; Chujo D; SoRelle J; Onaca N; Naziruddin B; Levy MF Cell Transplant; 2011; 20(10):1641-7. PubMed ID: 21396171 [TBL] [Abstract][Full Text] [Related]
14. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Maffi P; Bertuzzi F; De Taddeo F; Magistretti P; Nano R; Fiorina P; Caumo A; Pozzi P; Socci C; Venturini M; del Maschio A; Secchi A Diabetes Care; 2007 May; 30(5):1150-5. PubMed ID: 17259471 [TBL] [Abstract][Full Text] [Related]
15. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407 [TBL] [Abstract][Full Text] [Related]
16. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Posselt AM; Szot GL; Frassetto LA; Masharani U; Tavakol M; Amin R; McElroy J; Ramos MD; Kerlan RK; Fong L; Vincenti F; Bluestone JA; Stock PG Transplantation; 2010 Dec; 90(12):1595-601. PubMed ID: 20978464 [TBL] [Abstract][Full Text] [Related]
17. Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus. Bertuzzi F; Marazzi M; De Carlis LG; Rampoldi AG; Bonomo M; Antonioli B; Tosca MC; Galuzzi M; De Gasperi A; Colussi G Transplantation; 2016 Nov; 100(11):e117-e118. PubMed ID: 27517727 [No Abstract] [Full Text] [Related]
18. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816 [TBL] [Abstract][Full Text] [Related]
19. Islet of Langerhans allogeneic transplantation at the University of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations. Berney T; Bucher P; Mathe Z; Andres A; Bosco D; Mage R; Toso C; Oberholzer J; Becker C; Philippe J; Bühler L; Morel P Transplant Proc; 2004 May; 36(4):1121-2. PubMed ID: 15194390 [TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. Takita M; Matsumoto S; Shimoda M; Chujo D; Itoh T; Sorelle JA; Purcell K; Onaca N; Naziruddin B; Levy MF Clin Transplant; 2012; 26(5):E471-84. PubMed ID: 23061757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]